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Invasive procedures for prenatal diagnosis are associated with increased risk of abortion; thus, development of noninvasive
procedures would be beneﬁcial. Based on the observation that embryonic nucleated red blood cell (NRBC) crosses the placenta
and enters the circulation of pregnant women, the ability to identify such cell would allow development of such procedures.
Identiﬁcation of NRBCs in blood samples would be possible provided that speciﬁc antibodies are available. Here we have isolated
recombinant antibodies using phage display. From the panel of antibody fragments speciﬁcally recognising ε-Hb, one was chosen
for further characterization, DAb1. DAb1 binds to ε-Hb both in Western blots and immunocytochemistry. Several ε-Hb positive
cells were detected in a blood sample taken as postchorionic villus sampling (CVS). To evaluate the sensitivity of the method, K562
cells (which express ε-Hb) were spiked in a blood sample followed by staining in solution and FACS analysis.
Copyright © 2009 Morten Dræby Sørensen et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Today, prenatal diagnosis of chromosomal anomalies and
genetic disorders is routinely performed by invasive proce-
dures (e.g., chorionic villus sampling (CVS) and amniocen-
tesis). These techniques are highly accurate, but sustain risk
of miscarriage, ∼0,5% [1]. Isolation and analysis of intact
foetal nucleated cells in maternal blood during pregnancies
has been suggested as a method of noninvasive prenatal
diagnosis. In 1969, foetal cells were ﬁrst detected circulating
the maternal bloodstream [2]. Embryonic erythroblasts
(immature red blood cells), embryonic lymphocytes, and
trophoblast cells have all been pursued as sources of foetal
genomicmaterial.Embryonicerythroblastshavesincedrawn
most attention [3] due to a short and deﬁnite life span (15
minutes) resulting in a reduced risk of misdiagnosis from
previous pregnancies [4].
The Hb expression proﬁle of embryonic NRBCs diﬀers
from that of adult blood cells. The expression of Hb in
the embryo and foetus can be divided in three overlapping
periods, corresponding to the major haematopoietic organ:
mesoblastic (yolk sac), hepatic (liver and spleen), and
myeloid (bone marrow) [5, 6]. Human embryonic ζ-a n dε-
Hb are synthesised in yolk sac-derived primitive erythroid
cells [7] and are followed by the hepatic period extending
from the 10th to the 24th gestational week. In this period
foetal Hbs are expressed and are initiated with expression
of β-Hb then γ-Hb and later the adult Hb (α2β2)[ 8].
Three genes encode the α-like globins (5 -ζ-α2-α1-3 )a n d
ﬁve genes the β-like globins (5 -ε-Gγ-Aγ-δ-β-3 ), which are
expressed in a developmental sequence that parallels their
structural arrangement [8–10], giving rise to 141 and 146
amino acid residues, respectively.
The most speciﬁc marker for foetal erythroblasts is the
ε-Hb chains as expression of the other foetal Hbs has been
demonstrated in adult tissue [11–15]. A monoclonal anti-
bodyhaspreviouslybeendescribed,mouseantihaemoglobin
(ε-Chain). Applied Imaging, however, a panel of antibodies
recognising the same antigen, is advantageous in order to
increase speciﬁcity and decrease the risk of identiﬁcation2 Journal of Biomedicine and Biotechnology
of false positive. Recombinant antibodies oﬀer additional
advantages over traditional monoclonal antibodies with
respect to generating vast quantities and genetically linking
of active moieties.
Sincetheinitialdescriptionofsystemsallowingdisplayof
fusion proteins on the surface of ﬁlamentous bacteriophage
by Smith in 1985 [16], generation of scFv antibodies from
phage antibody libraries have proven to be an eﬃcient way
toproducespeciﬁcantibodies.Themajoradvantageofphage
display is the linkage between phenotype and genotype [16].
This enables selection of phage displaying antibodies against
any given antigen and at the same time isolation of the
corresponding gene encoding the antibody.
Here we have used phage display as a tool to select
antibodies against the ε-Hb chain, for the purpose of
applying these in noninvasive prenatal diagnosis.
2.MaterialsandMethods
2.1. Production of Recombinant Epsilon Haemoglobin.
HBE1 (Haemoglobin, Epsilon 1, RZPD clone ID:
IRAKp961B1722Q2) was obtained from RZPD (Deutsches
Ressourcenzentrum f¨ ur Genomforschung GmbH,
Germany).
The coding sequence of the HBE1 was ampliﬁed by
PCR with primers introducing NdeI and XhoI cloning sites
and cloned into the expression vector pET-21c. pET-21c-
HBE1 was transfected into BL21(DE3)pLysS by electropora-
tion and used for expression. Bacterial expression cultures
were grown with 10μM haemin (Hemin Bovine, Sigma-
Aldrich Denmark A/S, Denmark) and induced with 1mM
IPTG (isopropyl β-D-thio-galactopyranoside). Puriﬁcation
was performed according to the manufactures instructions
(Batch puriﬁcation of 6xHis-tagged proteins from E. coli
under denaturing conditions; Qiagen, The QIAexpressionist,
protocol 17). The amount and purity of puriﬁed ε-Hb were
checked by Bradford analysis and SDS-PAGE.
2.2. Cell Culture. The human erythroleukemia cell line K562
was grown as described elsewhere [17]. Haemin (Hemin
Bovine,Sigma-AldrichDenmarkA/S,Denmark)wassupple-
mented to culture medium to induce Hb expression [18].
2.3. Blood Samples. Foetal and maternal blood samples were
obtained from pregnant women after informed consent.
The samples from pregnant women were all taken in the
ﬁrst trimester. Embryonic nucleated red blood cells were
enriched by MACS (magnetic activated cell sorting) with
CD71-Dynabeads (Dynabeads M-450 CD71, Dynal ASA,
Oslo, Norway).
2.4. Single Chain Antibody Selection. An immunotube
(Nunc) was coated overnight at 4◦C with recombinant
ε-Hb in coating buﬀer (50mM NaHCO3,p H9 . 6 ) .D u e
to precipitation of the ε-Hb, the proteins were coated by
diluting the urea denatured protein 1 : 7 in coating
buﬀer, thus keeping the Urea concentration 1M. Residual
binding was blocked by incubating with 2% MPBS (2%
weight/volume low fat milk powder in Phosphate Buﬀered
Saline (PBS)), before 2.5 × 1012 phage particles representing
the Griﬃn 1 scFv library [19] in 2% MPBS were added
and incubated for 2 hours. Nonbound phage antibodies
were eliminated by washing 10 times with PBS/0,05% tween
20 and 10 times with PBS. Bound phage antibodies were
eluted in 0.5mL trypsin (1mg/mL) in 50mM Tris/HCl pH
7,4,1mM CaCl2 and used to infect E. coli, TG-1. Single
phage antibody clones were picked and rescued for ELISA
using the KM13 helper phage [20]; remaining colonies were
scraped of the plate and propagated for phage production.
The resulting phage antibodies were applied in a second
round of selection. Single phage colonies were picked and
grown in 96 well plates for stock and phage production.
2.5. ELISA. Single phage antibody clones were screened
for binding to antigen in ELISA as previously described
[21], except that phages were rescued with KM13 helper
phage [22]. ELISA was carried out by coating extracts of
K562 cell, recombinant ε-Hb, BL21 cell extract, or adult
blood on ELISA plates (MAXI-sorp, NUNC, Denmark),
followed by blocking with 2% MPBS. Fifty μL of precleared
culture supernatant from phage antibody clones grown and
rescued monoclonally were added together with 50μLo f
4% MPBS and incubated for 2 hours. The ELISA plates
were washed and phages were detected with a 1 : 5000
dilution of antiM13-HRP conjugated antibody (Pharmacia).
The ELISA was developed with OPD (o-phenylenediamine)
tablets (DAKO, Denmark) according to the manufacturer’s
instructions. In the case of ELISA using pKBJ derivatives of
scFv antibodies these were detected with the anti-Myc tag
antibody (9E10) and an HRP-conjugated rabbit antimouse
antibody (DAKO, Denmark).
2.6. Western- and Dot Blots. Following SDS-PAGE and
transfer of proteins to nitrocellulose membranes, mem-
branes were incubated with phage antibodies or purifed
scFv derivatives and bound phage or scFv derivatives were
detected by incubation with antiM13-HRP conjugated or
9E10 followed by HRP-conjugated rabbit antimouse anti-
body, respectively. Blots were subsequently developed with
ECL plus Western Blotting Detection System according to
manufacturers instructions (Amersham Biosciences, UK).
2.7. Expression of Phage Antibodies in pKBJ3 Vector. The
antibody genes of the selected clones were recloned into
the pKBJ3 vector, as described [23], using the cloning sites
Nco1andNot1.Theantibodieswerepuriﬁedbyimmobilised
metal aﬃnity chromatography, Nickel beads (Ni-NTA). The
proteinconcentrationwasdeterminedwithBradfordreagent
and the purity by SDS-PAGE. Subsequently, antibodies
were further puriﬁed on a Q-sepharose column before
biotinylation(ECLProteinBiotinylationModule,Amersham
Bioscience) or conjugated directly with FITC (Fluorotag
FITC Conjugation Kit, Sigma).
2.8. Immunocytochemistry. Either blood or K562 cells were
dispersed on to the slides in a thin and uniform layerJournal of Biomedicine and Biotechnology 3
followed by drying. Cells with or without ﬁxation with 4%
paraformaldehyde were permeabilised by submerging into
cold(−20
◦C)methanolovernightat −20
◦C.Slideswerethen
washed and blocked with 2% MPBS. Subsequently, biotiny-
lated anti-ε-Hb antibody was added in 2% MPBS/0,05%
Tween 20 with gentle shaking. Bound antibody was detected
with Streptavidin-FITC. Coverglasses were mountered with
antifade (DAKO Fluorescent Mounting Medium, DAKO,
Denmark) or antifade containing DAPI to counterstain
the nuclei, after which the slides were examined in the
microscope.
2.9. Fluorescence In Situ Hybridization. X and Y chromoso-
mal analysis was performed to distinguish male embryonic
cells from maternal cells. This was done using CEP X (α
satellite) SpectrumAqua hybridising centromere of human
chromosome X (bands Xp 11.1-q11.1, locus DXZ1; Vysis;
Downers Grove, Ill, USA) and CEP Y (α satellite) Spectru-
mOrange hybridising centromere of human chromosome Y
(bands Yq 12, locus DYZ1; Vysis; Downers Grove, Ill, USA).
Hybridisations were performed as described elsewhere [24].
Brieﬂy, slides were equilibrated in PBS after immunocyto-
chemistry, reﬁxed in 2% paraformaldehyde for 2 minutes,
dehydrated in ethanol, and air-dried. The chromosomespe-
ciﬁc repeat probes were used according to the instructions
given by the supplier.
2.10. Automated Scanning. Cells stained with biotin-
conjugated DAb1 complexed to streptavidin-FITC and
DAPI stained nuclei were located by automatic scanning
(Applied Imaging) using RCDetect (rare cell detection)
scanner developed by MetaSystems (Altlußheim, Germany).
The algoritm was modiﬁed for embryonic cells in maternal
blood. Scanning of slides with blood samples from pre-CVS
and post-CVS was performed as described elsewhere [24].
2.11. Fluorescence-Activated Cell Sorting. Cell staining for
FACS was performed with FITC conjugated DAb1. FACS
analyses were performed using a Becton Dickenson FACS
Aria. FITC and propidium iodide were exited using a 488nm
Laser, FITC was collected through a 530/20nm band pass
ﬁlter, and propidium iodide was collected through a 595nm
long pass ﬁlter. Data is shown without compensation.
K562 cells were collected and washed with 1xPBS,
resuspended in ice-cold methanol and incubated for 10
minutes at −20
◦C. Subsequently cells were centrifuged and
washed with 1xPBS before immunostaining with DAb1
(20μg/mL). Cells were washed 3 times with PBS and mixed
withﬁxednonstainedK562.ImmunostainingofK562spiked
into blood was performed according to same protocol.
3. Results
Recombinant ε-Hb was expressed in BL21(DE3)pLysS giving
highproteinyields(approximately10mgε-Hb/litreculture).
Under various culture conditions inclusion bodies were
formed, and therefore puriﬁcations were performed under
denaturing conditions (8M urea). Subsequent removal of
urea led to aggregation, and selections were carried out on
denatured ε-Hb. Selections were carried out with Griﬃn
VHVL library [19], yielding approximately 3000 selected
clones, of which 384 were tested monoclonally in ELISA
against recombinant ε-Hb. This led to the identiﬁcation of
26 binders (6.7%), 1 strong, and 25 weak binders. A second
round of selection was performed to increase the number
of positive clones. From the second round 384 clones were
tested monoclonal in ELISA, and 46% of these recognised
recombinant ε-Hb. Twelve clones speciﬁcally recognised
both denatured and native ε-Hb and showed no cross-
reactivity to paternal Hbs (α-a n dβ-Hb) (Table 1).
Sequencing of these 12 potentially speciﬁc antibodies
revealed four diﬀerent clones; one was represented 8 times
(DAb1), one was represented twice (1.9A), and two were
represented once (3.9G and 4.8E). The repeated representa-
tion of clones is normal, when performing more than one
round of selection. Clone DAb1, carried an Amber stop
codon within the reading frame. This was restored using site
directed mutagenesis. The four diﬀerent phage antibodies,
were tested in Western blot against a control protein
carrying a His-tag, extract from RBC, K562 cell extract, and
the recombinant ε-Hb (Figure 1). The four antibodies all
recognised puriﬁed ε-Hb together with one or more proteins
in the K562 extract. Several bands were present in the lane
containing the recombinant ε-Hb, representing monomers,
dimmers, and higher complexes of the ε-Hb chain. None of
theantibodiesrecognisedtheHis-tagprotein;however,clone
3.9G showed a very weak recognition of one protein in the
RBC extract.
All of the four antibody sequences were subcloned to
the pKBJ3 vector [23] and two clones of each antibody were
tested for expression. Three were chosen for further studies
due to their levels of expression in test experiments: 1.9A.1,
3.9G.2, and DAb1. The puriﬁed antibodies were biotinylated
and their activity was tested in ELISA, all conﬁrming the
activity toward the recombinant ε-Hb (data not shown).
To establish the optimal permeabilisation procedure for
cell immunostaining, the antibody fragments were tested in
Dot-blots where cells treated with diﬀerent permabilisation
regimes were tested (data not shown). The optimal treat-
ments of the cells were with methanol alone or mixed with
a c e t o n e( 1:1o r1:3 ) ,f o l l o w e db ys t o r a g ea t−20
◦C
over night. Initially immunocytochemistry with antibody
DAb1 performed on methanol ﬁxed and permeabilised K562
culture cells showed intense staining, compared to non-
stained cells (data not shown). One of the antibodies gave
a signiﬁcant better staining than the other three antibodies,
the DAb1. DAb1 stained approximately 10% of the cells in
an embryonic blood sample (ﬁrst trimester) demonstrating
the presence of several ε-Hb containing erythroblasts (data
not shown). A blood sample taken post-CVS (week 10 +
3) from a woman carrying a male foetus was enriched
for foetal cells by CD-71 directed MACS and subsequently
analysed as well. MACS-enriched cells obtained from a
2mL blood sample were coated on slides. The two slides
were permeabilised with methanol, and immunostaining
was subsequently performed with DAb1. After conﬁrming
that the slides contained stained cells, FISH was performed4 Journal of Biomedicine and Biotechnology
Table 1: Speciﬁcity of the 384 selected antibody clones obtainted from the second round of selection against ε-Hb, tested in ELISA towards
diﬀerent antigens. E: recombinant denatured ε-Hb. RBC: parental red blood cell extract (containing α-a n dβ-Hb, but no ε-Hb), BL21:
bacterial control cell extract, and K562: K562 cell extract (containing α-, γ-, δ-, ε-, and ζ-Hb). Neg.: amount of clones not recognising any
of the tested antigens. E+RBC, E+BL21, E+K562, and E+K562−BL21−RBC, amount of clones recognising ε-Hb (E) together with other
antigens. A total of 178 (46%) of the tested clones (384) gave positive ELISA signal toward ε-Hb, while 57 (15%) recognised K562 cell
extract. Only two clones recognised K562 cell extract without recognising ε-Hb. Twelve of the selected antibodies showed speciﬁcity of the
ε-Hb, since they recognised the denatured recombinant ε-Hb, the K562 extract, containing native ε-Hb and not the parental RBC, nor the
BL21 extract.
E RBC BL21 K562 E+RBC E+BL21 E+K562 E+K562−BL21−RBC Neg.
178 10 30 57 10 19 55 12 206
DAb1 1.9A 4.8E 3.9G Ponceau
HRKE H R K E HRKE HRKE HRKEM
64 64
36
22
16
36
16
(a) (b) (c) (d) (e)
Figure 1: Western blots performed with antibodies, DAb1(a), 1.9A(b), 4.8E(c), and 3.9G(d). The four diﬀerent clones each recognises the
recombinant ε-Hb, giving a correct band of 17kDa (ε-Hb protein fused with His-Tag; adding 8 amino acids). Furthermore they all recognise
a slightly smaller band of 146 amino acid residues in the K562 extract, containing the ε-Hb. A diﬀerence is observed for the recognised band
in the lane containing the recombinant ε-Hb and the ε-Hb in the K562 extract. Lane H: a control his-tagged protein, R: adult red blood cell
extract, K: K562 cell extract, and E: recombinant ε-Hb chain (2,5μg). (e) Representative ponceau staining of the blotted proteins. M: the
marker.
against the X- and Y-chromosomes. Scanning of the slides
revealed 129 cells identiﬁed as foetal erythroblasts, since
they were positive by both Y-chromosomes directed FISH
and immunocytochemistry for ε-Hb (Table 2 and Figure 2).
This corresponds to one embryonic NRBC pr 7.8 × 107
maternal blood cells. Several cells were damaged during the
FISH procedure because methanol is not strong enough
as a ﬁxative for the harsh conditions associated with
FISH analysis. Subsequent staining, after paraformaldehyde
ﬁxation, revealed as strong or stronger staining of cells
(not shown), and makes the cell more resistant towards
the FISH procedure, which will lead to a higher FISH
eﬃciency.
Future prenatal diagnosis methods are desired to be
applied on maternal blood samples; we therefore obtained
blood samples from two pregnant women, pre-CVS. Ten mL
of blood, 5 × 1010 blood cells (5mL each, taken week 8 + 4
and 9 + 0, resp.) was subjected to CD71 directed MACS and
stained with DAb1. No ε-Hb positive cells were found when
examining ten slides each coated with enriched blood cells
from approximately 1mL blood.
The lack of identiﬁed cells could be a result of the enrich-
ment procedure; however, in order to avoid performing
such enrichment, methods with a higher throughput such as
FACS have to be applied. To explore the feasibility of using
DAb1 to stain cells for ﬂow cytometric analysis we mixed
K562 cells stained with DAb1 with nonstained K562 cells,
followed by FACS analysis. As can be seen in Figure 3(a) two
Figure 2: Staining of enriched maternal blood sample taken as
post-CVS. First enrichment performed by CD-71 directed MACS.
Subsequently cells were mounted on glass slides and permeabilized
with methanol followed by immunostaining with FITC conjugated
DAb1 (30 μg/mL). Subsequently FISH was performed to kary-
otype the cells. Embryonic nucleated red blood cells (primitive
erythroblasts) identiﬁed with DAb1, directly conjugated with FITC
(green) is shown. Subsequently, FISH was performed against both
the X- (blue) and Y-chromosomes (red), conﬁrming the origin of
the immunostained cells. X-chromosomes of nonimmunostained
nucleated maternal cells (seen as blue dots), are located around the
identiﬁed foetal erythroblasts.
p o o l sa p p e a r e d .F u r t h e r m o r eF A C Sw a sp e r f o r m e do nb l o o d
sample spiked with K562 (Figure 3(b)). A population of cells
is seen in the ﬁgure, consisting of K562 cells, conﬁrmed byJournal of Biomedicine and Biotechnology 5
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Figure 3: Flow cytometric analysis of (a) stained and nonstained K562. The lower circle shows the non-DAb1 stained cells while upper circle
shows the stained cells (P1). All cells have been ﬁxed, permeabilised, and PI stained before cytometry. (b) K562 cells spiked into paternal
blood sample. Figure 3 shows 106 cell events. The P1 shows the population of stained K562 among the blood cells.
Table 2: Summary of FISH analysis on post-CVS blood. Most
identiﬁed cells contain an XY signal, while those not containing
both a Y and an X-signal were damaged by the FISH procedure.
A total of 129 embryonic NRBC were identiﬁed from the post-CVS
sample. FISH eﬃciencies were 96% for the Y chromosome and 84%
for the X-chromosome.
FISH-signal Intact Damaged Total
XY 35 73 108
XX 0 0 0
Y 0 16 16
X0 1 1
None 0 4 4
Total 35 94 129
staining and morphology by microscopy (data not shown),
thus providing proof of concept.
4. Discussion
Previous attempts have been performed to select speciﬁc
antibodies against foetal or embryonic erythroblasts, both by
others [25, 26] and ourselves (data not shown). In our case
we did not succeed, due to a limited availability of foetal cell.
Instead we selected on the only known speciﬁc antigen of
theembryonicerythroblast;ε-Hbanddiﬃcultieshaslikewise
been reported with regard to the antibodies selected by Huie
et al. as discussed by Bianchi and Hanson [27].
It has previously been shown that the ε-Hb chain
is diﬃcult to purify [28]. We overcame this problem
by purifying recombinant ε-Hb chain under denaturing
conditions in 8M urea buﬀers, leading to a yield, high
enough for performing antibody selections by phage display.
The selections were performed using urea denatured puri-
ﬁed antigen directly coated on a solid surface preventing
aggregation. Previously reports have described selections
made on denatured antigen, but only as a side eﬀect of
puriﬁcation. In some cases the antigen was puriﬁed by SDS-
PAGE [29, 30]. In other cases antigens were transferred to
nitrocellulose membranes after SDS-PAGE [31, 32]. In all
cases, antibodies were able to recognise antigen in Western
blot.
We succeeded in selecting a speciﬁc human antibody
against the ε-Hb chain by the use of phage display. Compar-
ison with previous staining obtained with mouse anti-ε-Hb
antibody [24] the selected human antibody fragment, DAb1,
gives similar staining of NRBC. Previous attempts resulted
in isolation of antibody fragments with cross-reactivity to
other Hb-chains [33]. Our selected antibody, DAb1 revealed
only one band against the K562 extract, in Western blot
(Figure 1). This band corresponds to the higher of the two
haemoglobin bands, seen on the ponceau staining. This
representsa mixtureof the β like globin genes,whichcontain
the ε-Hb, while the lower band represents the α like globin
genes.
This study illustrates that “you get what you select for.”
Here we have shown that antibodies that recognise ε-Hb
chain speciﬁcally can be selected, and established that (i) it is
feasible to select antibodies against urea denatured antigens
and (ii) selections can be directed towards recognition of
sequenceinsteadofstructure.Thisnewselectionmethodcan
be very useful in future studies, where it is essential to obtain
antibodies that recognise the antigen in Western blots. Also,
there are many cases in which it is diﬃcult to obtain pure
native folded protein, avoiding aggregation, in such cases
this method will allow the production of speciﬁc antibody
fragments.6 Journal of Biomedicine and Biotechnology
The usage of automated scanning oﬀers a high-
throughput screening method for the identiﬁcation of foetal
cells in a maternal blood sample, either by scanning for
immunostained cells or Y-chromosomes containing cells
after FISH [34–36]. However, it is a time-consuming and
laborious work to validate the identiﬁed cells due to a
high percentage of false positives. Enrichment procedures
reducing the amount of maternal cells are therefore required
for usage of automated scanning in noninvasive prenatal
diagnostics.
Immunocytochemistry, combined with automated scan-
ning, will enable us to estimate the number of embryonic
NRBCs in blood samples taken from pregnant women post-
and pre-CVS. Comparing the numbers of NRBCs in the
samples taken as post-CVS corresponds well with those
reported by others. In the staining on the pre-CVS blood
samples no embryonic NRBCs were detected. To date there
is no conclusive evidence on the number of embryonic
NRBCs in the maternal bloodstream during pregnancy. The
reports are many, and quantitations have been performed in
diﬀerent ways. The ﬁrst reliable report performed on a pre-
CVS sample estimated around 1 cell per mL maternal blood
[3].Laterreportsestimatebetween1–5cellspermLmaternal
blood [15, 37, 38], depending of the method of enrichment.
Others have however found foetal NRBC at much lower
frequencies [39–41].
Traditionally CD71 have been used to enrich the fraction
of foetal cells. Results obtained by Choolani et al. [39], have
shown that embryonic, like foetal erythroblasts were GPA+,
CD47+, CD45−, and CD35−, whereas CD71 expression
was almost undetectable on embryonic erythroblast but
strongly expressed by foetal erythroblasts [39]. Furthermore,
all embryonic erythroblasts expressed ε-Hb, whereas less
than 0.06% of the foetal erythroblasts expressed this Hb
chain. This raises the question whether the CD71 selection
actually is appropriate for selection of ε-Hb positive NRBCs.
By FISH we were able to establish that at least 96.1%
of the antibody stained NRBCs were of embryonic origin.
This eﬃciency is comparable with those obtained by others
[42]. The FISH procedure partly destroyed several of the
cells, because ﬁxation of the cells was only performed with
methanol, making the cells fragile to the hard treatment of
the FISH procedure. Most important is however the fact that
noidentiﬁedantibodystainedcellsweredetectedwithtwoX-
chromosomes, conﬁrming that ε-Hb exclusively is found in
NRBC of embryonic origin. Alternatively, the combination
of markers could potentially be used with expression of ε-Hb
forFACSisolationofNRBCs.Itislikelythatthecombination
of markers will enable the isolation of an essentially pure
population of cells.
The paraformaldehyde ﬁxation of the K562 cells resulted
in a background of autoﬂuorescence, as seen on Figure 3.
A small background is also observed on a variety of blood
cell types. Although the autoﬂuorescence on blood cells has
been observed to be almost undetectable on the majority of
cell types, it is unlikely that FACS can be used as a method
for obtaining pure samples of ε-Hb positive cells, but as an
enrichment method. To ensure that no cells are lost before
the FACS, it is vital to perform FACS on nonenriched blood
samples. However, removal of erythrocytes would make the
enrichment procedure much faster and increase the purity.
If FACS procedure is to be successfully applied, as a high-
throughput enrichment method, it will have to be combined
with another enrichment procedure that does not lead to a
loss of any embryonic erythroblasts.
We have, by the FACS of the K562 immunostained by
DAb1 and the spiked samples, obtained a gate for sorting out
ε-Hb antibody stained cells. This gate will make it possible
to enrich ε-Hb positive embryonic NRBCs from a maternal
blood sample. Following FACS enrichment identiﬁcation of
individual embryonic NRBC can be performed by micro-
scopic analysis.
We have shown that DAb1 recognises ε-Hb chain specif-
ically, conﬁrmed by FISH that ε-Hb positive cells are of
foetal origin and validated ε-Hb as a cellular marker for
embryonicNRBCs.Inordertoapplytheanti-ε-Hbantibody,
DAb1, for prenatal diagnosis high-throughput methods like
FACS analysis would have to be introduced due to the low
frequency of circulating cells.
5. Conclusion
The inherent problem with any noninvasive prenatal diag-
nosis procedure is the low abundance of foetal cells in the
maternal blood, thus requiring sensitive high-throughput
methods. Here we have isolated a recombinant antibody,
DAb1, with a potential use in high-throughput noninvasive
prenataldiagnosis,whencombinedwithnewfastinstrumen-
tation for FACS. The recombinant antibody can be produced
by bacterial expression, thus allowing cost eﬀective large
scale production. By applying the recombinant antibody in
prenatal diagnosis, it is possible to remove the increased risk
of abortion associated with invasive procedures.
Abbreviations
NRBC: Nucleated red blood cells
RBC: Red blood cells
Hb: Haemoglobin
FACS: Fluorescence-activated cell sorter
CVS: Chorionic villus sampling
MACS: Magnetic Activated Cell Sorting
FISH: Fluorescence in situ hybridization
ELISA: Enzyme-linked immunosorbent assays.
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